Callan Family Office’s Sempra SRE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.02M Sell
21,823
-1,235
-5% -$115K 0.04% 384
2026
Q1
$2.24M Sell
23,058
-403
-2% -$36.9K 0.05% 324
2025
Q4
$2.07M Buy
23,461
+14,664
+167% +$1.34M 0.04% 347
2025
Q3
$792K Sell
8,797
-3,790
-30% -$307K 0.03% 422
2025
Q2
$954K Buy
12,587
+8,824
+234% +$655K 0.03% 418
2025
Q1
$269K Sell
3,763
-105
-3% -$8.18K 0.02% 452
2024
Q4
$339K Buy
+3,868
New +$339K 0.02% 454

Other funds holding SRE

Callan Family Office's SRE Position: Q2 2026 in Review

Callan Family Office reduced its Sempra (SRE) stake by 5.4% in Q2 2026, selling an estimated $115K and leaving 21,823 shares worth $2.02M. The position accounts for 0.04% of the portfolio, ranked #384.

Callan Family Office first reported a position in SRE in Q4 2024 and has held it in 7 quarters since. The position peaked at $2.24M in Q1 2026. 1,282 funds tracked by Wall St. Rank hold SRE as of Q2 2026.

  • Callan Family Office held 21,823 shares of Sempra worth $2.02M as of Q2 2026.
  • Callan Family Office sold 1,235 Sempra shares in Q2 2026, an estimated $115K.
  • Sempra made up 0.04% of Callan Family Office's portfolio in Q2 2026, its #384 holding.
  • Callan Family Office first reported a position in Sempra in Q4 2024 and has held it in 7 quarters since.
  • Callan Family Office's Sempra position peaked at $2.24M in Q1 2026.
  • 1,282 funds tracked by Wall St. Rank held Sempra as of Q2 2026.

Based on Callan Family Office's 13F filing for Q2 2026, filed 11 Aug 2026.